Drugs / Cell-culture
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03598439 | Jul 2018 → Mar 2020 | influenza | Marshfield Clinic Research Foundation | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-10-14 | CSL Behring | Results The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to < 18 Years of Age csl.com ↗
Summit, NJ, USA 14 Oct 2021 Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine has published absolute efficacy data on the company’s cell-based quadrivalent influenza vaccine (QIVc) from a randomized controlled trial (RCT) which met its primary endpoint. |
| 2018-12-05 | CSL Behring | Results Next Generation Cell-based Influenza Vaccine Shows Significantly Greater Effectiveness Compared to Standard Egg-based Options in the 2017-18 US Influenza Season csl.com ↗
The rVE estimated from the study’s primary analysis indicated that QIVc was more effective than standard egg-based QIVs in preventing ILI (rVE of 36.2%, 95% CI (26.1,44.9; P<0.001)). |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cell-culture | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03598439 ↗ |
| Modality | Vaccine | “licensed cell-culture influenza vaccine” NCT03598439 ↗ |